None listed
Conditions
Interventions
Drug : 1. Eflapegrastim (Rolontis prefilled syringe 0.6ml) is administered as a subcutaneous injection 24 hours after completion of chemotherapy on day 1 of the first cycle.
2. On day 7 of the first
Sponsors
Eunseong Medical Foundation Good Gang-an Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Women aged 18 to 75 years old as of the date of study registration. Patients with histologically confirmed invasive adenocarcinoma. Patients with confirmed estrogen receptor, progesterone receptor, and Her2 receptor status. Patients with ECOG performance status 0-1. Patients with a left ventricular ejection fraction (LVEF) =55%. Patients who have agreed to participate in this trial and have provided written consent.
Exclusion criteria
Exclusion criteria: Patients with a history of breast cancer treatment Patients with a history of chemotherapy, radiation therapy, immunotherapy, or biotherapy for malignancies other than breast cancer Patients with infectious diseases Patients with serious illnesses that may affect this clinical trial: cardiovascular disease, kidney disease, liver disease, endocrine disease, tumors, or diabetes Other individuals deemed by the clinical trial investigators to be unable to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence rate of severe neutropenia | — |
Secondary
| Measure | Time frame |
|---|---|
| duration of severe neutropenia;Incidence rate of febrile neutropenia;incidene rate of neutropenia related death | — |
Countries
Korea, Republic of
Contacts
Public ContactJangmoo Byeon
Eunseong Medical Foundation Good Gang-an Hospital
Outcome results
None listed